STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2010 by analyst upside · 2026-08-13
ARWR
Arrowhead Pharmaceuticals, Inc.
Healthcare · Market Cap $12B · P/E 0x
ANALYST PRICE TARGET
+26.3%
implied upside to consensus target
Current Price $87.25
Consensus Target $110.18
Bull Target $126.0
Bear Target $100.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
7
Hold
0
Sell
0
52-Week Low $18.09
52-Week High $95.49
YTD Return +28.7%
FUNDAMENTALS
Market Cap $12B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.23
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $669M
Profit Margin -47.8%
52-WEEK RANGE
52-Week Low $18.09
52-Week High $95.49
Current Price $87.25
Bear Target $100.0
Bull Target $126.0
● Now $87.25 ● Target $110.18
TRADING DATA
Avg Volume 2.2M
YTD Return +28.7%
Analyst Count 11
Consensus Buy
Upside to Target +26.3%
Last Updated 2026-08-13

ANALYST SUMMARY

Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $87.25 with a Wall Street consensus price target of $110.18, implying potential upside of 26.3% over the next 12 months. 11 analysts currently cover ARWR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $126.0, while the most cautious has a target of $100.0.

ARWR operates in the Healthcare sector with a market capitalisation of $12B. The stock is up 28.7% year-to-date and is currently trading near the upper end of its 52-week range of $18.09 – $95.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ARWR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners - Reiterated
Market Perform → Market Perform 2026-06-17 29% win rate (7 calls)
Bernstein - Reiterated
Market Perform → Market Perform 2026-05-13 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-05-08 Building track record
JP Morgan ● Initiated
Overweight 2026-05-01 43% win rate (7 calls)
Morgan Stanley ↑ Upgrade
Equal-Weight → Overweight 2026-04-21 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-25 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-10 31% win rate (48 calls)
B. Riley Securities - Reiterated
Buy → Buy 2026-01-22 17% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
70
out of 100
Coverage depth
19/30
Consensus clarity
24/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →